Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | SDHB | P21912 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450686 | 1.00 | MEN1 (0.45) | MEN1GAAKMT2APTGS2DAO | |
| SCHEMBL5461655 | 0.85 | PTGS2 (0.50) | MEN1GAAKMT2APTGS2DAO | |
| SCHEMBL5461659 | 0.85 | PTGS2 (0.50) | MEN1GAAKMT2APTGS2DAO | |
| SCHEMBL5463544 | 0.84 | MLNR (0.47) | MEN1GAAKMT2ATSHRCA1 | |
| SCHEMBL5459294 | 0.83 | MAPT (0.40) | MEN1GAAKMT2ATSHRCA1 | |
| SCHEMBL5465687 | 0.83 | MAOA (0.39) | MEN1GAAKMT2APTGS2TSHR | |
| SCHEMBL5450671 | 0.82 | ESR2 (0.44) | MEN1GAAKMT2APTGS2PTPN1 | |
| SCHEMBL5460065 | 0.78 | TNFRSF1A (0.48) | MEN1GAAKMT2APTGS2DAO | |
| SCHEMBL5460063 | 0.78 | TNFRSF1A (0.48) | MEN1GAAKMT2APTGS2DAO | |
| SCHEMBL5465032 | 0.77 | TXNRD1 (0.44) | CA1CA2MMP2MMP14MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004799-A1 | Novel compounds for the treatment of obesity | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | claimed |
| EP-1689707-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | claimed |
| WO-2005051900-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | claimed |
| US-20070004799-A1 | Novel compounds for the treatment of obesity | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
| US-20070004799-A1 | Novel compounds for the treatment of obesity | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
| US-20070004799-A1 | Novel compounds for the treatment of obesity | NOVO NORDISK A/S (DK) | 2007-01-04 | — | — | US | disclosed |
| EP-1689707-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051900-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004799-A1 | Novel compounds for the treatment of obesity | GPR119, NR4A3, NR4A1 | MEN1 4657/4885GAA 3558/4885KMT2A 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.